Market Overview

Momenta Pharmaceuticals Falls 17% on Patent Infringement Ruling

Related MNTA
Momenta Pharmaceuticals Spikes Up Following FDA News On Copaxone
Benzinga's M&A Chatter for Tuesday March 31, 2015
Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q1 2015 Results - Earnings Call Transcript (Seeking Alpha)

Momenta Pharmaceuticals (NASDAQ: MNTA) is trading lower on the session after announcing that Teva Pharmaceutical (NASDAQ: TEVA) received a favorable ruling in COPAXONE patent infringement case. The decision is subject to appeal.

Craig Wheeler, President and Chief Executive Officer of Momenta. "We are disappointed that the court determined that Teva's patents were valid and infringed, and we look forward to reading the full opinion to understand its reasoning. We remain confident in our legal position and we intend to appeal."

Momenta Pharmaceuticals is currently trading at $14.02, a loss of $2.99 or 17.61%.

Posted-In: Intraday Update Movers


Related Articles (MNTA + TEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters